Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis

Fig. 1

Schematic representation of pembrolizumab therapeutic protocol. Eight-to-10 week old male C57B6/J mice were randomly assigned in the following groups: (1) saline, (2) saline + high dose pembrolizumab, (3) bleomycin, (4) bleomycin + low dose pembrolizumab, (5) bleomycin + high dose pembrolizumab (Fig. 1). Pembrolizumab (A2005, Selleckchem) was diluted in saline as recommended by the supplier at a final concentration of 1.5 mg/mL and was injected intraperitoneally on days 8, 10 and 12 following bleomycin administration (Day 0). High dose pembrolizumab stands for 10 mg/kg, 5 mg/kg and 5 mg/kg on days 8, 10 and 12, respectively. Low dose pembrolizumab stands for 5 mg/kg, 2.5 mg/kg and 2.5 mg/kg on days 8, 10 and 12, respectively. On day 14, Ashcroft score, body weight, total protein, cellularity and respiratory mechanics were compared among the aforementioned groups. Nine mice were initially used for each arm (total: 9 mice for 5 arms-45 mice)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us